Cargando…

Antitumor activity of a potent MEK inhibitor, TAK-733, against colorectal cancer cell lines and patient derived xenografts

BACKGROUND: CRC is a significant cause of cancer mortality, and new therapies are needed for patients with advanced disease. TAK-733 is a highly potent and selective investigational novel MEK allosteric site inhibitor. MATERIALS AND METHODS: In a preclinical study of TAK-733, a panel of CRC cell lin...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lieu, Christopher H., Klauck, Peter J., Henthorn, Patrick K., Tentler, John J., Tan, Aik-Choon, Spreafico, Anna, Selby, Heather M., Britt, Blair C., Bagby, Stacey M., Arcaroli, John J., Messersmith, Wells A., Pitts, Todd M., Eckhardt, S. Gail
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2015
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4741473/ https://www.ncbi.nlm.nih.gov/pubmed/26439693

Ejemplares similares

Antitumor activity of the polo-like kinase inhibitor, TAK-960, against preclinical models of colorectal cancer
por: Klauck, Peter J., et al.
Publicado: (2018)

Combined inhibition of MEK and Aurora A kinase in KRAS/PIK3CA double-mutant colorectal cancer models
por: Davis, S. Lindsey, et al.
Publicado: (2015)

Antitumor activity of the aurora a selective kinase inhibitor, alisertib, against preclinical models of colorectal cancer
por: Pitts, Todd M., et al.
Publicado: (2016)

Dual Pharmacological Targeting of the MAP Kinase and PI3K/mTOR Pathway in Preclinical Models of Colorectal Cancer
por: Pitts, Todd M., et al.
Publicado: (2014)

Dual compartmental targeting of cell cycle and angiogenic kinases in colorectal cancer models
por: Capasso, Anna, et al.
Publicado: (2018)

Association of the epithelial-to-mesenchymal transition phenotype with responsiveness to the p21-activated kinase inhibitor, PF-3758309, in colon cancer models
por: Pitts, Todd M., et al.
Publicado: (2013)

Antitumor effects of the investigational selective MEK inhibitor TAK733 against cutaneous and uveal melanoma cell lines
por: von Euw, Erika, et al.
Publicado: (2012)

Evaluation of the therapeutic efficacy of a MEK inhibitor (TAK-733) using (18)F-fluorodeoxyglucose-positron emission tomography in the human lung xenograft model A549
por: Ishino, Seigo, et al.
Publicado: (2015)

MEK inhibitor, TAK-733 reduces proliferation, affects cell cycle and apoptosis, and synergizes with other targeted therapies in multiple myeloma
por: de la Puente, P, et al.
Publicado: (2016)

A phase I dose-escalation study of TAK-733, an investigational oral MEK inhibitor, in patients with advanced solid tumors
por: Adjei, Alex A., et al.
Publicado: (2016)

Evaluation of the efficacy of dasatinib, a Src/Abl inhibitor, in colorectal cancer cell lines and explant mouse model
por: Scott, Aaron J., et al.
Publicado: (2017)

The novel ATM inhibitor (AZ31) enhances antitumor activity in patient derived xenografts that are resistant to irinotecan monotherapy
por: Greene, Justin, et al.
Publicado: (2017)

TAK-733 inhibits inflammatory neointimal formation by suppressing proliferation, migration, and inflammation in vitro and in vivo
por: Park, Jun-Hee, et al.
Publicado: (2018)

WEE1 Inhibition in Combination With Targeted Agents and Standard Chemotherapy in Preclinical Models of Pancreatic Ductal Adenocarcinoma
por: Hartman, Sarah J., et al.
Publicado: (2021)

An integrated bioinformatics analysis to dissect kinase dependency in triple negative breast cancer
por: Ryall, Karen A, et al.
Publicado: (2015)

Characterization of immune responses to anti-PD-1 mono and combination immunotherapy in hematopoietic humanized mice implanted with tumor xenografts
por: Capasso, A., et al.
Publicado: (2019)

Wee1 Inhibition Enhances the Anti-Tumor Effects of Capecitabine in Preclinical Models of Triple-Negative Breast Cancer
por: Pitts, Todd M., et al.
Publicado: (2020)

A Phase I Dose‐Escalation Study of Linsitinib (OSI‐906), a Small‐Molecule Dual Insulin‐Like Growth Factor‐1 Receptor/Insulin Receptor Kinase Inhibitor, in Combination with Irinotecan in Patients with Advanced Cancer
por: Davis, S. Lindsey, et al.
Publicado: (2018)

The novel tankyrase inhibitor (AZ1366) enhances irinotecan activity in tumors that exhibit elevated tankyrase and irinotecan resistance
por: Quackenbush, Kevin S., et al.
Publicado: (2016)

Efficacy and Molecular Mechanisms of Differentiated Response to the Aurora and Angiogenic Kinase Inhibitor ENMD-2076 in Preclinical Models of p53-Mutated Triple-Negative Breast Cancer
por: Ionkina, Anastasia A., et al.
Publicado: (2017)

Complete Draft Genome Sequence of Escherichia coli JF733
por: Kleiner, Gabriele R. M., et al.
Publicado: (2016)

Tumours with elevated levels of the Notch and Wnt pathways exhibit efficacy to PF-03084014, a γ-secretase inhibitor, in a preclinical colorectal explant model
por: Arcaroli, J J, et al.
Publicado: (2013)

From Bench to Bedside: Lessons Learned in Translating Preclinical Studies in Cancer Drug Development
por: Lieu, Christopher H., et al.
Publicado: (2013)

ATM and MET kinases are synthetic lethal with non-genotoxic activation of p53
por: Sullivan, Kelly D., et al.
Publicado: (2012)

Utilization of Quantitative In Vivo Pharmacology Approaches to Assess Combination Effects of Everolimus and Irinotecan in Mouse Xenograft Models of Colorectal Cancer
por: Bradshaw-Pierce, Erica L., et al.
Publicado: (2013)

Biomarker-driven trial in metastatic pancreas cancer: feasibility in a multicenter study of saracatinib, an oral Src inhibitor, in previously treated pancreatic cancer
por: Arcaroli, John, et al.
Publicado: (2012)

RX-5902, a novel β-catenin modulator, potentiates the efficacy of immune checkpoint inhibitors in preclinical models of triple-negative breast Cancer
por: Tentler, John J., et al.
Publicado: (2020)

MEK inhibition abrogates sunitinib resistance in a renal cell carcinoma patient-derived xenograft model
por: Diaz-Montero, C Marcela, et al.
Publicado: (2016)

733 Vancomycin-Resistant Enterococcus (VRE) faecium Bloodstream Infections and Mortality
por: Suleyman, Geehan, et al.
Publicado: (2014)

The NK1 antagonist L-733,060 facilitates sequence learning
por: Favila, Natalia, et al.
Publicado: (2023)

Effect of leaf position and days post-infiltration on transient expression of colorectal cancer vaccine candidate proteins GA733-Fc and GA733-FcK in Nicotiana benthamiana plant
por: Kim, Kibum, et al.
Publicado: (2021)

SUN-733 Analysis of Divergent Long Noncoding RNAs in Estrogen-Regulated Transcription
por: Lee, Debra, et al.
Publicado: (2020)

The ATM and ATR inhibitors CGK733 and caffeine suppress cyclin D1 levels and inhibit cell proliferation
por: Alao, John P, et al.
Publicado: (2009)

Cabozantinib sensitizes microsatellite stable colorectal cancer to immune checkpoint blockade by immune modulation in human immune system mouse models
por: Lang, Julie, et al.
Publicado: (2022)

ALDH1B1 Is Crucial for Colon Tumorigenesis by Modulating Wnt/β-Catenin, Notch and PI3K/Akt Signaling Pathways
por: Singh, Surendra, et al.
Publicado: (2015)

Optimization of the human colorectal carcinoma antigen GA733-2 production in tobacco plants
por: Park, Se Hee, et al.
Publicado: (2021)

Clonal distribution of vancomycin‐resistant Enterococcus faecium in Turkey and the new singleton ST733
por: Erdem, Fatma, et al.
Publicado: (2020)

733 Development of TeleBurn Utilizing Hospital Based EMR and Stroke Robot Photography
por: Bernal, Nicole, et al.
Publicado: (2023)

TAK1 Phosphorylates RASSF9 and Inhibits Esophageal Squamous Tumor Cell Proliferation by Targeting the RAS/MEK/ERK Axis
por: Shi, Hui, et al.
Publicado: (2021)

BCL2L11 Induction Mediates Sensitivity to Src and MEK1/2 Inhibition in Thyroid Cancer
por: Rose, Madison M., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_0jregn4ogrgpltj2jrlcil8cmg